Galapagos may see takeover bid from Gilead this year, analyst says
Dutch-Belgian pharmaceutical research company Galapagos [AMS:GLPG] may receive a takeover bid from its partner US-based partner Gilead [NASDAQ:GILD] this year, an analyst told the Dutch daily De Telegraaf.
Analyst Jos Versteeg, who works with the private bank InsingerGilissen, said that there’s a reasonable chance that, if the test results of Galapagos’s new medicine against rheumatism are positive, Gilead will place a takeover bid on Galapagos in the second half of this year.
Galapagos made a turnover of EUR 101.9m in the first 6 months of 2018, an earlier report by De Telegraaf noted. It has a market cap of EUR 4.78bn
Link to original article